39 completed, 13 recruiting, 8 not yet recruiting, 7 active not recruiting. 77 Phase 3, 13 Phase 2.
Follow Alopecia: new trials by email Literature Review of Alopecia trials Research Report on Alopecia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. Minoxidil oral solution, Placebo oral solution - Androgenetic Alopecia, Androgenetic Alopecia (AGA) | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 372 | 2027-01-31 | 2026-11-06 |
| Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss DA-005, Topical minoxidil 5%, DA-002 - Androgenetic Alopecia, Female Pattern Baldness | Phase 3 | Withdrawn | Applied Biology, Inc. | 2027-01-15 | 2026-11-02 | |
| Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN) N1087, Placebo - Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 372 | 2027-01-01 | 2026-11-04 |
| Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial Botulinum Toxin Type A, Autologous Nanofat Injection - Androgenetic Alopecia | Phase 2 / Phase 3 | Not yet recruiting | Sherief Ayman Hussein Shaamash | 40 | 2026-12-01 | 2026-10-07 |
| Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia APSMNF 1, APSMNF 2, Eniagor® - Alopecia, Androgenetic | Phase 3 | Not yet recruiting | Apsen Farmaceutica S.A. | 336 | 2026-10-07 | 2026-09-08 |
| Phase 2/3 Efficacy and Safety of PP405 in Adult Males PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia | Phase 2 / Phase 3 | Recruiting | Pelage Pharmaceuticals, Inc. | 600 | 2026-09-21 | 2026-10-28 |
| A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata Upadacitinib, Placebo - Severe Alopecia Areata | Phase 3 | Recruiting | AbbVie | 300 | 2026-08-24 | 2026-10-27 |
| A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - Alopecia Areata | Phase 3 | Recruiting | Pfizer | 336 | 2026-07-30 | 2026-10-26 |
| Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata Deuruxolitinib, Placebo - Alopecia Areata | Phase 3 | Recruiting | Sun Pharma Japan Limited | 78 | 2026-06-19 | 2026-10-30 |
| Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth DA-001, Placebo, Phenylephrine - Telogen Effluvium, Female Pattern Hair Loss | Phase 2 / Phase 3 | Not yet recruiting | Applied Biology, Inc. | 1120 | 2026-05-01 | 2026-04-13 |
| Androgenic Alopecia TH07 Clinical Trial TH07, Minoxidil 5% Topical Solution, Placebo - Androgenic Alopecia | Phase 3 | Recruiting | Triple Hair Inc | 420 | 2026-04-01 | 2026-03-16 |
| Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia Minoxidil 5 % Topical Spray, minoxidil, Placebo Spray - Androgenic Alopecia | Phase 3 | Not yet recruiting | Sheikh Zayed Federal Postgraduate Medical Institute | 200 | 2025-12-20 | 2025-12-10 |
| A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. Ritlecitinib higher dose, Ritlecitinib lower dose - Severe Alopecia Areata | Phase 3 | Recruiting | Pfizer | 140 | 2025-09-10 | 2026-10-15 |
| Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata Deuruxolitinib, Placebo - Alopecia Areata | Phase 3 | Recruiting | Sun Pharmaceutical Industries, Inc. | 355 | 2025-08-05 | 2026-01-28 |
| A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo - Severe Alopecia Areata | Phase 3 | Active not recruiting | Pfizer | 208 | 2025-07-31 | 2026-11-06 |
| Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) VDPHL01 QD, Placebo, VDPHL01 BID - Androgenetic Alopecia (AGA), Androgenetic Alopecia | Phase 3 | Active not recruiting | Veradermics, Inc. | 552 | 2025-07-25 | 2026-08-17 |
| Efficacy & Safety of Minoxidil SL Tablets in Men With AGA Minoxidil, Placebo - Androgenetic Alopecia, Male Pattern Baldness | Phase 3 | Completed | Samson Clinical Operations Pty Ltd | 142 | 2025-07-14 | 2026-05-18 |
| A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata Upadacitinib, Upadacitinib Placebo - Alopecia Areata | Phase 3 | Active not recruiting | AbbVie | 125 | 2025-06-19 | 2026-07-30 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia CKD-843 dose#1, CKD-843 dose#2, Placebo of CKD-843 dose - Androgenetic Alopecia | Phase 3 | Recruiting | Chong Kun Dang Pharmaceutical | 288 | 2025-04-08 | 2026-09-03 |
| A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg - Alopecia Areata | Phase 3 | Recruiting | Pfizer | 674 | 2025-04-01 | 2026-10-20 |
Showing 20 of 77. Sign in to see all of them.
Alopecia Areata (28) · Hair Diseases (6) · Alopecia universalis (5) · Skin Diseases (2) · Cutis Laxa (1) · Hypotrichosis (1) · Pathological Conditions, Anatomical (1)
Skin and Connective Tissue Diseases (77) · Hypotrichosis (76) · Skin Diseases (75) · Hair Diseases (71) · Pathological Conditions, Signs and Symptoms (55) · Pathological Conditions, Anatomical (54) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Genetic Diseases, Inborn (1) · Skin Diseases, Genetic (1)
Minoxidil (16) · Dutasteride (5) · Solutions (5) · Finasteride (4) · baricitinib (3) · upadacitinib (3) · Clascoterone (2) · PF-06651600 (2) · BID protein, human (1) · Bexarotene (1) · Botulinum Toxins, Type A (1) · Capsules (1) · Ceramides (1) · Cetirizine (1) · Duration of Therapy (1)
Pfizer (6) · AbbVie (3) · Applied Biology, Inc. (3) · Eli Lilly and Company (3) · Eurofarma Laboratorios S.A. (3) · GlaxoSmithKline (3) · Sun Pharmaceutical Industries, Inc. (3) · Veradermics, Inc. (3) · Cassiopea SpA (2) · Concert Pharmaceuticals (2) · EMS (2) · Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. (2) · Suzhou Kintor Pharmaceutical Inc, (2) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2) · Universitas Indonesia (2)
United States (28) · Canada (15) · China (15) · Japan (15) · Germany (13) · France (12) · Spain (12) · Poland (11) · South Korea (11) · Brazil (9) · Taiwan (9) · United Kingdom (8) · Australia (7) · Argentina (6) · Hungary (6)
Andy Goren, MD (3) · Reid Waldman, M.D. (3) · Timothy Durso, M.D. (3) · Alessandro Mazzetti, M.D. (2) · Barbara Uzel, M.D (1) · Bruce Kohut, DMD (1) · Christina Weng (1) · Chuchai Tanglertsampan, MD (1)
PMID 35334197, PMID 36763878, PMID 36855020, PMID 37381691, PMID 37556146, PMID 37991697, PMID 38263353, PMID 38904749, PMID 39962358, PMID 40214720, PMID 41917311, PMID 42481842, PMID 42823604, PMID 42825995, PMID 17196507, PMID 23960389, PMID 24226568, PMID 24940651, PMID 26893187, PMID 27391640, PMID 28139263, PMID 28300084, PMID 29273099, PMID 30886475, PMID 31799258, PMID 32941917, PMID 33112463, PMID 34211288, PMID 36177791, PMID 36571611, PMID 36884234, PMID 37062298, PMID 37339501, PMID 37403610, PMID 37521227, PMID 37605227, PMID 37707764, PMID 37917289, PMID 37955531, PMID 39053611, PMID 39141364, PMID 39254890, PMID 39328096, PMID 39423930, PMID 39432738, PMID 39441519, PMID 39846397, PMID 40261547, PMID 40668972, PMID 40736519
2023 (2), 2009 (1), 2018 (1), 2025 (1)